Clinical Trials Browser

Phase 1/2 × Active not recruiting × Prostatic Neoplasms × Clear all

NCT03317392 2026-05-20

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Phase 1/2 Active not recruiting

132 enrolled 22 charts

Prostatic Neoplasms

NCT03217747 2026-05-05

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Phase 1/2 Active not recruiting

173 enrolled 28 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT05067140 2026-05-05

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Phase 1/2 Active not recruiting

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT04194554 2026-05-01

ASCLEPIuS

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05983198 2026-04-29

SatisfACtion

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT07117760 2026-04-29

Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT03543189 2026-04-01

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Phase 1/2 Active not recruiting

Prostatic Diseases, Prostatic Neoplasms

NCT06066437 2026-03-05

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05546268 2026-03-03

Study of Oral MRT-2359 in Selected Cancer Patients

Phase 1/2 Active not recruiting

BreastGenitourinaryLymphoidThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

NCT02522715 2026-02-24

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Phase 1/2 Active not recruiting

37 enrolled 10 charts

Prostatic Neoplasms

NCT04471727 2026-02-24

MK-6070-001

Phase 1/2 Active not recruiting

EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04644068 2026-02-19

PETRA

Phase 1/2 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04506567 2026-02-17

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT04478279 2026-02-09

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

BreastCNSDermatologicGenitourinary

Brain Neoplasms, Breast Neoplasms, Glioblastoma, Melanoma, Prostatic Neoplasms

NCT05968144 2026-01-27

ADRIAN

Phase 1/2 Active not recruiting

BreastGenitourinary

Frailty, Breast Neoplasms, Prostatic Neoplasms

NCT05367440 2025-12-08

PETRANHA

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05540392 2025-10-10

An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues

Phase 1/2 Active not recruiting

Prostatic Neoplasms, Nocturia

NCT03042468 2025-09-17

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Phase 1/2 Active not recruiting

50 enrolled 19 charts

Prostatic Neoplasms

NCT05011188 2025-08-27

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05864144 2025-08-15

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Carcinoma, Merkel Cell

NCT01688492 2025-08-12

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT04140526 2025-05-23

PRESERVE-001

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT03689699 2025-04-29

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Phase 1/2 Active not recruiting

59 enrolled 9 charts

Prostatic Neoplasms

NCT04619069 2025-04-17

Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05383079 2025-02-07

AlphaBet

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05547061 2024-12-11

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT04430192 2024-11-08

LuTectomy

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05003752 2023-03-07

Hypo-Combi

Phase 1/2 Active not recruiting

Prostatic Neoplasms, Radiation Injuries

NCT03444844 2022-05-02

Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer

Phase 1/2 Active not recruiting

Prostatic Neoplasms